Research animal retirement and lifetime care, now available through Alpha Genesis. Professionally managed lifetime care for retired research primates, with expert social reintroduction into stable outdoor groups led by veterinary staff deeply experienced in laboratory-animal medicine.
Learn moreClients
Alpha Genesis partners with pharmaceutical and biotechnology sponsors across the United States, Europe, and Asia on program-level preclinical execution, from rodent proof-of-concept through translational NHP studies, with GLP and non-GLP options, audit-ready documentation suitable for international development programs, and responsiveness that supports global development timelines.
Pharmaceutical and biotechnology sponsors, from multinational organizations to focused biotechs across the United States, Europe, and Asia, require a CRO partner that combines scientific depth, operational discipline, and regulatory-compliance readiness. Alpha Genesis supports programs spanning early discovery through IND-enabling stages, with species capabilities that include mice, rats, rhesus macaques, cynomolgus macaques, African green monkeys, and capuchins, with custom programs available for additional species on request, in an integrated, AAALAC-accredited facility environment.
Our approach is built on board-certified laboratory-animal veterinary leadership, decades of NHP colony management, SOP-driven operations, GLP quality systems consistent with internationally recognized expectations, and sponsor audit readiness, with IACUC oversight of every protocol. GLP and non-GLP study support is available for research clients, enabling a single-partner relationship from exploratory proof-of-concept through in vivo work designed to support global regulatory submissions. Capabilities are matched to your program during protocol review.
Responsiveness matters in drug development. Our dedicated scientific project managers and study directors engage from early scoping through final deliverables, coordinating across time zones where programs require it, providing scientific input, operational transparency, and the documentation infrastructure that supports internal review and submissions to major health authorities, including the FDA, EMA, MHRA, PMDA, and others, where appropriate.
We understand the priorities that drive outsourcing decisions in pharmaceutical and biotech drug development. Our capabilities are structured to address the following sponsor needs.
The ability to run non-GLP exploratory studies and GLP regulatory-track studies within the same CRO reduces logistical overhead, preserves institutional knowledge across program stages, and simplifies vendor qualification.
Translational NHP studies, including repeat-dose toxicology, safety pharmacology, PK/PD, and immunogenicity assessment in cynomolgus or rhesus macaques, conducted by teams experienced in designing studies that fit a global regulatory strategy and meet the expectations of both U.S. and international health authorities.
Sponsors conducting regulated studies require sponsor-audit access, SOP-governed operations, structured records, and a facility culture that treats documentation as integral to scientific work, producing data packages suitable for international development programs and submissions across multiple jurisdictions.
Serial and terminal biospecimen collection, processing, cryopreservation, and logistics from both rodent and NHP studies, with chain-of-custody documentation, cold-chain shipping, cross-border logistics, and worldwide sample management.
Drug development timelines are not forgiving. Sponsors need a CRO that provides timely protocol review, clear feasibility assessments, and proactive communication throughout the program, with flexible meetings across time zones for globally distributed teams. With ready colony access from the largest NHP colony in the United States, we move quickly.
Reliable, reproducible data starts with exceptional animal care, not baseline compliance. Sponsors benefit from board-certified laboratory-animal veterinarians, 24/7/365 veterinary and clinical care, enrichment and behavioral-management programs, and preventive medicine delivered in an AAALAC-accredited facility, all of which protect study integrity and regulatory confidence.
The following service areas are most commonly engaged by pharmaceutical and biotech sponsors, including IND-enabling NHP and rodent studies with GLP-aligned documentation. Scope is confirmed during protocol review.
Alpha Genesis supports pharmaceutical and biotechnology programs across both NHP and rodent species, enabling integrated rodent-to-NHP program strategies within a single CRO relationship, an advantage for multinational development programs that value continuity from one partner.
The most widely used NHP species in regulated safety evaluation, with broad regulatory precedent for toxicology, safety pharmacology, PK/PD, and immunogenicity programs.
Learn moreA well-characterized translational model for infectious disease, vaccine research, immunology, CNS pharmacology, and safety studies with extensive published scientific precedent.
Learn moreA natural-host model for infectious disease, virology, and immunology programs, with colony access and study support for sponsor-defined objectives.
Learn moreA New World primate model supported on a sponsor-specific basis for specialized pharmacology, neuroscience, and translational program requirements.
Learn moreGLP and non-GLP rodent capabilities for PK/PD, dose-ranging, toxicology, immunology, oncology, and surgical model studies with serial and terminal collection.
Learn moreLess-common NHP and specialized models supported on a program-specific basis, drawing on deep multi-species veterinary and operational experience.
Learn moreAlpha Genesis pairs deep scientific and veterinary capability with the operational discipline pharmaceutical and biotech sponsors require from a primary or supplemental CRO partner.
Compliance is expected; exceptional animal care is what differentiates a study program. Board-certified veterinarians, around-the-clock clinical care, enrichment and behavioral management, and decades of NHP colony management produce the reliable data your program depends on, helping us consistently generate high-quality regulatory data, backed by a quality framework that supports regulated execution, sponsor audits, and international development programs.
Rodent and NHP study support within a single AAALAC-accredited, USDA-licensed facility simplifies vendor qualification, reduces logistical overhead, and maintains program continuity across species.
Seamless transitions from non-GLP exploratory studies to GLP regulatory studies within the same facility and with the same scientific team preserves institutional program knowledge and reduces re-qualification burden.
Animal supply and in-life study execution within the same organization reduces logistical handoffs, supports timeline predictability, and maintains data traceability from colony to study report.
SOP-governed procedures, structured documentation, and sponsor audit programs provide the transparency and records quality that regulated pharmaceutical study programs require.
On-site veterinary professionals and experienced study directors provide protocol consultation, in-life oversight, and clinical expertise across NHP and rodent programs.
Alpha Genesis operates at a scale where individual programs receive dedicated scientific and operational attention, with scientific project managers providing proactive communication, across time zones and borders, throughout study conduct.
Yes. GLP and non-GLP study support is available for research clients. GLP applicability is confirmed during protocol review based on study design, objectives, and model. Submit a protocol to confirm suitability for your program, including studies intended to support global regulatory submissions.
Submit a protocol for review or request a consultation to discuss study design, species selection, GLP applicability, global regulatory strategy, and program timeline with our scientific and operations team.
